| Inhibitory effect of vitamin K(2) on interleukin-1beta-stimulated proliferationof human osteoblasts. | Biol Pharm Bull | 2010 | 20460758 |
| Warfarin interactions with substances listed in drug information compendia and inthe FDA-approved label for warfarin sodium. | Clin Pharmacol Ther | 2009 Oct | 19587643 |
| Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guideddosing in patients starting warfarin therapy. | Clin Pharmacol Ther | 2009 Nov | 19571807 |
| Vitamin K in parenteral nutrition. | Gastroenterology | 2009 Nov | 19874942 |
| Will a once-weekly anticoagulant for the treatment and secondary prevention ofthromboembolism improve adherence? | Thromb Haemost | 2009 Mar | 19277401 |
| Erythrocyte folate and 5-methyltetrahydrofolate levels decline during 6 months oforal anticoagulation with warfarin. | Blood Coagul Fibrinolysis | 2009 Jun | 19349858 |
| Atmospheric pressure changes and unexplained variability in INR measurements. | Blood Coagul Fibrinolysis | 2009 Jun | 19300239 |
| CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose incarriers of the V433M variant. | Mol Pharmacol | 2009 Jun | 19297519 |
| The absence of an interaction between warfarin and cranberry juice: a randomized,double-blind trial. | J Clin Pharmacol | 2009 Jul | 19553405 |
| Chiral toxicology: it's the same thing...only different. | Toxicol Sci | 2009 Jul | 19414517 |